This study provides an important clue to explain why convalescent plasma (CP) was not more effective in treating severe COVID-19 in the first wave of the COVID-19 global pandemic. The findings may influence how medical experts deploy and test the efficacy of convalescent plasma for other infections in the future.
The purpose of the study was to understand why convalescent plasma did not improve outcomes in severe disease. Mount Sinai researchers believe that the success of convalescent plasma in treating the COVID-19 was related to antibody cross activities against related common cold virus.